Episode 13 afterward: The biopharma glass is definitively more than half-full
Justin, Todd, and special guest Robert Groebel, VP of global life science strategy at Definitive Healthcare, expand on last week’s chat with Pam Randhawa from Empiriko and unpack the challenges, benefits, and opportunities of collaboration in the biopharma market.
How can big pharma, small pharma, academia, and the government all work together? Robert and Todd have some big ideas. They look back at their careers to share professional insights and personal perspectives on the biopharma industry’s evolving playbook—and why they’re looking forward with a healthy dose of optimism.
Justin asks Todd and Robert to answer some big questions: What can biopharma orgs do to address healthcare equity? Is there an insurmountable divide between the industry’s profit motive and academia’s educational mission? And what has Robert feeling so optimistic about biopharma’s impact on patients and caregivers?
